IDEXX Laboratories (IDXX) Stock Buyback History
TTM buyback yield 2.59% · Shareholder yield (TTM) 2.59%.
TTM buyback yield
2.59%
Shareholder yield (TTM)
2.59%
5Y share count change
-7.0%
TTM buyback spend
$1.17B
SBC coverage (TTM)
15.87x
YoY change in spend
+45.4%
5Y CAGR of spend
+46.1%
Peak year (2025)
$1.22B
Cumulative spend
$7.97B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- IDEXX Laboratories (IDXX) repurchased about $1.17B of stock over the trailing twelve months.
- Diluted share count is down 7.0% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 15.87× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +46.1% per year over the latest 5-year window.
- TTM repurchases used about 108% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $1.22B | $0.00 | $1.22B | 0.08B | -3.1% | 2.25% |
| 2024 | $837.03M | $60.30M | $776.74M | 0.08B | -0.9% | 2.47% |
| 2023 | $71.92M | $59.74M | $12.18M | 0.08B | -0.7% | 0.16% |
| 2022 | $819.71M | $49.77M | $769.94M | 0.08B | -2.3% | 2.42% |
| 2021 | $746.78M | $37.76M | $709.02M | 0.09B | -0.2% | 1.34% |
| 2020 | $182.81M | $30.95M | $151.86M | 0.09B | -0.9% | 0.43% |
| 2019 | $301.66M | $39.28M | $262.38M | 0.09B | -1.0% | 1.35% |
| 2018 | $369.32M | $25.16M | $344.16M | 0.09B | -1.2% | 2.30% |
| 2017 | $290.64M | $23.52M | $267.12M | 0.09B | -1.4% | 2.13% |
| 2016 | $304.09M | $19.89M | $284.19M | 0.09B | -3.0% | 2.90% |
| 2015 | $401.98M | $19.88M | $382.10M | 0.09B | -7.7% | 6.07% |
| 2014 | $618.16M | $18.10M | $600.06M | 0.10B | -6.0% | 8.73% |
| 2013 | $367.76M | $16.54M | $351.22M | 0.11B | -3.9% | 6.65% |
| 2012 | $132.27M | $15.95M | $116.32M | 0.11B | -3.5% | 2.60% |
| 2011 | $255.50M | $15.50M | $240.01M | 0.12B | -2.3% | 6.01% |
| 2010 | $143.09M | $13.26M | $129.83M | 0.12B | -1.9% | 3.60% |
| 2009 | $83.10M | $11.62M | $71.48M | 0.12B | -2.5% | 2.68% |
| 2008 | $132.34M | $10.50M | $121.84M | 0.12B | -3.4% | 6.20% |
| 2007 | $118.39M | $8.78M | $109.61M | 0.13B | -2.2% | 3.32% |
| 2006 | $105.71M | $10.84M | $94.87M | 0.13B | -3.2% | 4.28% |
| 2005 | $123.77M | $135.00K | $123.63M | 0.14B | -4.9% | 5.41% |
| 2004 | $129.19M | $135.00K | $129.06M | 0.14B | -0.4% | 7.18% |
| 2003 | $35.82M | $138.00K | $35.68M | 0.14B | 2.5% | 2.23% |
| 2002 | $29.83M | $0.00 | $29.83M | 0.14B | 1.2% | 2.71% |
| 2001 | $12.99M | $0.00 | $12.99M | 0.14B | -4.0% | 1.34% |
| 2000 | $70.26M | $0.00 | $70.26M | 0.14B | -9.2% | — |
| 1999 | $64.20M | $0.00 | $64.20M | 0.16B | 4.6% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.15B | 0.9% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.15B | -4.1% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.16B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for IDEXX Laboratories (IDXX) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for IDEXX Laboratories (IDXX)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for IDEXX Laboratories (IDXX)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $1.22B | +45.4% | +$379.93M | ||
| 2024 | $837.03M | +1063.8% | +$765.11M | ||
| 2023 | $71.92M | -91.2% | -$747.79M | ||
| 2022 | $819.71M | +9.8% | +$72.93M | ||
| 2021 | $746.78M | +308.5% | +$563.96M | ||
| 2020 | $182.81M | -39.4% | -$118.84M | ||
| 2019 | $301.66M | -18.3% | -$67.66M | ||
| 2018 | $369.32M | +27.1% | +$78.68M | ||
| 2017 | $290.64M | -4.4% | -$13.45M | ||
| 2016 | $304.09M | -24.4% | -$97.89M | ||
| 2015 | $401.98M | -35.0% | -$216.18M | ||
| 2014 | $618.16M | +68.1% | +$250.40M | ||
| 2013 | $367.76M | +178.0% | +$235.49M | ||
| 2012 | $132.27M | -48.2% | -$123.24M | ||
| 2011 | $255.50M | +78.6% | +$112.42M | ||
| 2010 | $143.09M | +72.2% | +$59.99M | ||
| 2009 | $83.10M | -37.2% | -$49.24M | ||
| 2008 | $132.34M | +11.8% | +$13.96M | ||
| 2007 | $118.39M | +12.0% | +$12.68M | ||
| 2006 | $105.71M | -14.6% | -$18.06M | ||
| 2005 | $123.77M | -4.2% | -$5.42M | ||
| 2004 | $129.19M | +260.7% | +$93.37M | ||
| 2003 | $35.82M | +20.1% | +$5.99M | ||
| 2002 | $29.83M | +129.7% | +$16.84M | ||
| 2001 | $12.99M | -81.5% | -$57.27M | ||
| 2000 | $70.26M | +9.4% | +$6.06M | ||
| 1999 | $64.20M | — | +$64.20M | ||
| 1998 | $0 | — | $0 | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | — | $0 | ||
| 1995 | $0 | — | $0 | ||
| 1994 | $0 | — | $0 | ||
| 1993 | $0 | — | $0 | ||
| 1992 | $0 | — | $0 | ||
| 1991 | $0 | — | — |
The 2025 reading of IDEXX Laboratories (IDXX) buyback spend is $1.22B – surged 45.4% year-over-year.
IDEXX Laboratories buyback spend has grown for 2 consecutive years, with a +46.1% compound annual growth rate over 2020–2025 (5 years).
The highest annual buyback spend of $1.22B was reported in 2025. The lowest in the available history was $0 in 1991.
Among 8 Healthcare peers, IDEXX Laboratories (IDXX) ranks 6th; the peer median for buyback spend is $2.75B.
IDEXX Laboratories Buyback Spend 2025: $1.22B
IDEXX Laboratories buyback spend in 2025 was $1.22B, surged 45.4% from 2024. This figure represents the highest annual value in the available history.
IDEXX Laboratories Buyback Spend 2024: $837.03M
IDEXX Laboratories buyback spend in 2024 was $837.03M, surged 1063.8% from 2023.
IDEXX Laboratories Buyback Spend 2023: $71.92M
IDEXX Laboratories buyback spend in 2023 was $71.92M, plunged 91.2% below 2022.
IDEXX Laboratories Buyback Spend 2022: $819.71M
IDEXX Laboratories buyback spend in 2022 was $819.71M, grew 9.8% from 2021.
IDEXX Laboratories Buyback Spend 2021: $746.78M
IDEXX Laboratories buyback spend in 2021 was $746.78M.
See more financial history for IDEXX Laboratories (IDXX).
Sector peers by buyback spend
Companies in the same sector as IDEXX Laboratories, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 15.87×.
Capital allocation mix
How IDEXX Laboratories splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.08B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from IDEXX Laboratories's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does IDEXX Laboratories buy back its own stock?
Yes, IDEXX Laboratories (IDXX) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does IDEXX Laboratories spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $1.17B (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is IDEXX Laboratories's buyback yield?
TTM buyback yield is about 2.59% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is IDEXX Laboratories's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 2.59% combined (TTM-based where available).
Is IDEXX Laboratories diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has IDEXX Laboratories's share count changed?
Diluted weighted average shares changed by about -7.0% over roughly five fiscal years (annual income statement data).
What is IDEXX Laboratories's buyback spend?
Latest reported buyback spend for IDEXX Laboratories (IDXX) is $1.17B (period ending March 31, 2026).
How has IDEXX Laboratories buyback spend changed year-over-year?
IDEXX Laboratories (IDXX) buyback spend changed +45.4% year-over-year on the latest annual filing.
What is the long-term growth rate of IDEXX Laboratories buyback spend?
IDEXX Laboratories (IDXX) buyback spend compound annual growth rate is +46.1% over the most recent 5 years available.
When did IDEXX Laboratories buyback spend hit its highest annual value?
IDEXX Laboratories buyback spend reached its highest annual value of $1.22B in 2025.
What was IDEXX Laboratories buyback spend in 2024?
IDEXX Laboratories (IDXX) buyback spend in 2024 was $837.03M.
What was IDEXX Laboratories buyback spend in 2025?
IDEXX Laboratories (IDXX) buyback spend in 2025 was $1.22B.
Explore more
IDXX Overview
Company profile, financial tools, and key metrics
IDXX Revenue Counter
Earns $140.98 every second. See per minute, hour, and day.
IDXX Earnings Counter
Earns $34.73 per second net profit. See per minute, hour, and day.
IDXX Economic Scale
Exceeds Suriname's GDP. Compare with world economies.
IDXX What If Invested
What if you had invested $1,000? See historical returns from any date.
IDXX How It Makes Money
Discover visual breakdown of $4.45B in revenue — where it comes from and where it goes.
IDXX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
IDXX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
IDXX Daily Price Character
Explosive · 50.9% historical win rate (green days). Streaks & record days.
IDXX Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.
IDXX Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.